Literature DB >> 15572029

GDNF-induced leukemia inhibitory factor can mediate differentiation via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous knockout mice.

Jong-In Park1, James F Powers, Arthur S Tischler, Christopher J Strock, Douglas W Ball, Barry D Nelkin.   

Abstract

Glial cell line-derived neurotrophic factor (GDNF) can induce neuron-like differentiation of mouse pheochromocytoma (MPC) cell lines derived from mice with a heterozygous knockout mutation of nf1, the murine counterpart of the human gene mutated in neurofibromatosis type 1 (NF1). Here, we show that GDNF-induced differentiation in the MPC 862L cell line is mediated by the MEK/extracellular signal-regulated kinase (ERK) pathway. Neurite outgrowth, increased expression of growth-associated protein 43, and decreased incorporation of bromodeoxyuridine (BrdU) were induced by treatment with GDNF, H-RasV12, or a constitutively active MEK2. GDNF also induces leukemia inhibitory factor (LIF) via the MEK/ERK pathway, and LIF itself can elicit these differentiative changes via a cell-extrinsic autocrine/paracrine pathway. Treatment with anti-LIF neutralizing antibody depleted the differentiative activity of the conditioned medium from cells stimulated for MEK/ERK signaling, while recombinant LIF could induce differentiation in MPC cells, indicating that LIF is the sole factor with differentiative activity. LIF could activate MEK1/2 and STAT3, but LIF-induced differentiation was blocked only by the MEK1/2-specific inhibitor U0126, indicating that the MEK/ERK pathway is necessary for LIF action in MPC cells. Our findings suggest that LIF may be utilized for signaling mediated by GDNF and may be important in the pathobiology of neuroendocrine tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15572029     DOI: 10.1016/j.yexcr.2004.09.028

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  11 in total

1.  Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice.

Authors:  Dmytro Starenki; Nishant K Singh; Davin R Jensen; Francis C Peterson; Jong-In Park
Journal:  Cancer Lett       Date:  2013-07-12       Impact factor: 8.679

2.  The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells.

Authors:  Seung-Keun Hong; Jin-Hwan Kim; Ming-Fong Lin; Jong-In Park
Journal:  Exp Cell Res       Date:  2011-08-16       Impact factor: 3.905

3.  Growth arrest signaling of the Raf/MEK/ERK pathway in cancer.

Authors:  Jong-In Park
Journal:  Front Biol (Beijing)       Date:  2014-02

4.  Noncatalytic function of ERK1/2 can promote Raf/MEK/ERK-mediated growth arrest signaling.

Authors:  Seung-Keun Hong; Seunghee Yoon; Cas Moelling; Dumrongkiet Arthan; Jong-In Park
Journal:  J Biol Chem       Date:  2009-10-05       Impact factor: 5.157

5.  A cellular threshold for active ERK1/2 levels determines Raf/MEK/ERK-mediated growth arrest versus death responses.

Authors:  Seung-Keun Hong; Pui-Kei Wu; Jong-In Park
Journal:  Cell Signal       Date:  2017-10-03       Impact factor: 4.315

6.  LIF upregulates expression of NK-1R in NHBE cells.

Authors:  Cheng-Ping Hu; Jun-Tao Feng; Yu-Ling Tang; Jin-Qi Zhu; Min-Juan Lin; Ming-En Yu
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

7.  RAS and beyond: the many faces of the neurofibromatosis type 1 protein.

Authors:  Corina Anastasaki; Paola Orozco; David H Gutmann
Journal:  Dis Model Mech       Date:  2022-02-21       Impact factor: 5.732

8.  Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors.

Authors:  Su-Jin Park; Birgit Sawitzki; Lan Kluwe; Victor F Mautner; Nikola Holtkamp; Andreas Kurtz
Journal:  BMC Med       Date:  2013-04-23       Impact factor: 8.775

Review 9.  Molecular and cellular biology of pheochromocytomas and extra-adrenal paragangliomas.

Authors:  Arthur S Tischler
Journal:  Endocr Pathol       Date:  2006       Impact factor: 4.056

10.  The Role of STAT3 in Thyroid Cancer.

Authors:  Nadiya Sosonkina; Dmytro Starenki; Jong-In Park
Journal:  Cancers (Basel)       Date:  2014-03-06       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.